CSIMarket



Immucell Corp  (ICCC)
Other Ticker:  
 
 

ICCC's Operating Income Growth by Quarter and Year

Immucell's Operating Income results by quarter and year




ICCC Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 0.15 -0.63 -0.67
III Quarter September - 0.27 -0.25 -
II Quarter June -0.62 0.22 -0.69 -0.55
I Quarter March 0.79 -0.37 0.20 0.27
FY   0.17 0.27 -1.37 -0.95



ICCC Operating Income second quarter 2022 Y/Y Growth Comment
Immucell Corp in the second quarter 2022 recorded Operating Loss of $ -0.62 millions.

Looking into second quarter 2022 results within In Vitro & In Vivo Diagnostic Substances industry 4 other companies have achieved higher Operating Income growth. While Immucell Corp' s Operating Income no change of % ranks overall at the positon no. 2188 in the second quarter 2022.

Explain Operating Income growth


ICCC Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - -25.93 % -
FY   - - - -

Financial Statements
Immucell's second quarter 2022 Operating Income $ -0.62 millions ICCC's Income Statement
Immucell's second quarter 2021 Operating Income $ 0.22 millions Quarterly ICCC's Income Statement
New: More ICCC's historic Operating Income Growth >>


ICCC Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -44.44 % - -
III Quarter September - 22.73 % - -
II Quarter June - - - -
I Quarter March 426.67 % - - -
FY (Year on Year)   - - - -




Operating Income second quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #5
Healthcare Sector #168
Overall #2188

Operating Income Y/Y Growth Statistics
High Average Low
453.64 % 96.56 % -58.56 %
(Mar 31 2022)   (Jun 30 2022)
Operating Income second quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #5
Healthcare Sector #168
Overall #2188
Operating Income Y/Y Growth Statistics
High Average Low
453.64 % 96.56 % -58.56 %
(Mar 31 2022)   (Jun 30 2022)

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Immucell's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ICCC's II. Quarter Q/Q Operating Income Comment
Recent results of -0.62 millions by Immucell Corp look even more unfavourable compare to the Operating Loss 0.79 millions in the first quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Immucell Corp achieved highest sequential Operating Income growth. While Immucell's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ICCC's II. Quarter Q/Q Operating Income Comment
II. Quarter 2022 Operating Loss of -0.62 millions by Immucell Corp appear even worse compare to the 0.79 millions Operating Loss in the previous quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Immucell Corp achieved highest sequential Operating Income growth. While Immucell's Operating Income growth quarter on quarter, overall rank is .


Immucell's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Operating Income 12 Months Ending $ 0.59 $ 1.42 $ 0.26 $ -0.52 $ -1.05
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) -58.56 % 453.64 % - - -
Seq. Operating Income Growth (TTM) Overall Ranking # 2188 # 17 # 0 # 0 # 0




Cumulative Operating Income growth Comment
In the Jun 30 2022 period, Immucell had cumulative twelve months Operating Income of $ 1 millions compare to Operating Loss of $ -1 millions a year ago.

Immucell Corp achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
453.64 %
96.56 %
-58.56 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall # 0

Operating Income TTM Y/Y Growth Statistics
High Average Low
232.93 %
138.6 %
44.28 %
(March 31, 2016)  


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 168
S&P 500 # 2188
Cumulative Operating Income growth Comment
In the Jun 30 2022 period, Immucell had cumulative twelve months Operating Income of $ 1 millions compare to Operating Loss of $ -1 millions a year ago.

Immucell Corp achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
453.64 %
96.56 %
-58.56 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall # 0

Operating Income TTM Y/Y Growth Statistics
High Average Low
232.93 %
138.6 %
44.28 %
(March 31, 2016)  


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 168
S&P 500 # 2188




Other Operating Income Growth
In Vitro & In Vivo Diagnostic Substances Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
ICCC's Operating Income Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for ICCC's Competitors
Operating Income Growth for Immucell's Suppliers
Operating Income Growth for ICCC's Customers

You may also want to know
ICCC's Annual Growth Rates ICCC's Profitability Ratios ICCC's Asset Turnover Ratio ICCC's Dividend Growth
ICCC's Roe ICCC's Valuation Ratios ICCC's Financial Strength Ratios ICCC's Dividend Payout Ratio
ICCC's Roa ICCC's Inventory Turnover Ratio ICCC's Growth Rates ICCC's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Jun 30 2022
Addus Homecare Corporation-0.90%$ -0.903 millions
Hca Healthcare Inc.-1.20%$ -1.198 millions
Corcept Therapeutics Inc-1.60%$ -1.600 millions
Bio rad Laboratories Inc.-3.66%$ -3.658 millions
Diversified Healthcare Trust-4.01%$ -4.006 millions
Prestige Consumer Healthcare Inc.-4.74%$ -4.738 millions
Conmed Corporation-4.86%$ -4.859 millions
Tenet Healthcare Corp-5.63%$ -5.631 millions
National Research Corporation-6.07%$ -6.071 millions
Encompass Health Corporation-7.56%$ -7.562 millions
Sotera Health Company-8.66%$ -8.658 millions
United Therapeutics Corporation-9.18%$ -9.181 millions
Adapthealth Corp.-9.52%$ -9.523 millions
Gilead Sciences Inc.-9.66%$ -9.662 millions
U S Physical Therapy Inc-9.67%$ -9.672 millions
Pacira Biosciences inc.-10.36%$ -10.355 millions
Davita Inc.-11.78%$ -11.777 millions
Neurocrine Biosciences Inc.-12.90%$ -12.898 millions
Bruker Corporation-13.67%$ -13.668 millions
Eli Lilly And Company-13.77%$ -13.774 millions
Innoviva Inc.-14.49%$ -14.487 millions
Becton Dickinson And Company-14.49%$ -14.490 millions
Ironwood Pharmaceuticals inc.-14.51%$ -14.506 millions
Edwards Lifesciences Corporation-15.24%$ -15.237 millions
Baxter International Inc.-19.81%$ -19.811 millions
Semler Scientific inc.-19.89%$ -19.895 millions
Moderna Inc.-20.08%$ -20.085 millions
Ethema Health Corporation.-21.03%$ -21.027 millions
Reynolds Consumer Products Inc.-21.85%$ -21.849 millions
Intuitive Surgical Inc.-22.22%$ -22.222 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

COTY's Profile

Stock Price

COTY's Financials

Business Description

Fundamentals

Charts & Quotes

COTY's News

Suppliers

COTY's Competitors

Customers & Markets

Economic Indicators

COTY's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071